(Q39801855)

14 September 2017

title

Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. (English)

1 reference

14 September 2017

0 references

1 reference

1 reference

D D Cui

1

1 reference

14 September 2017

Y Huang

2

1 reference

14 September 2017

S H Mao

3

1 reference

14 September 2017

S C Chen

4

1 reference

14 September 2017

M Qiu

5

1 reference

14 September 2017

L L Ji

6

1 reference

14 September 2017

C Yi

7

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Brazilian Journal of Medical and Biological Research

14 September 2017

published in

1 reference

14 September 2017

volume

42

1 reference

14 September 2017

issue

9

1 reference

14 September 2017

page(s)

854-862

1 reference

Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

TRAIL and cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

The clinical trail of TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

The promise of TRAIL--potential and risks of a novel anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Induction of apoptosis by cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

The role of TRAIL death receptors in the treatment of hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

TRAIL/Apo-2L: mechanisms and clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

p53 upregulates death receptor 4 expression through an intronic p53 binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0100-879X2009000900013

10.1590/S0100-879X2009000900013

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference